Grufity logoGrufity logo

NVCR

80.04USD-1.50(-1.84%)Market Closed

Novocure Ltd

Market Summary

USD80.04-1.50Market Closed
-1.84%

NVCR Alerts

NVCR Stock Price

RSI Chart

Valuation

Market Cap

7.4B

Price/Earnings

-90

Price/Sales

13.55

Price/Cashflow

150.36

MarketCap/EBT

-98.21

Price/Sales

Profitability

Operating Margin

78.68%

EBT Margin

-13.80%

Return on Equity

-18.34%

Return on Assets

-6.96%

Fundamentals

Revenue

Revenue (TTM)

542.6M

Revenue Y/Y

-1.95%

Revenue Q/Q

-7.01%

Earnings

Earnings (TTM)

-81.7M

Earnings Y/Y

-102.5%

Earnings Q/Q

-10.7%

Price Action

52 Week Range

94.00
(Low)(High)

Last 7 days

6.7%

Last 30 days

12.2%

Last 90 days

1.8%

Trailing 12 Months

-12.4%

Financial Health

Current Ratio

7.81

Debt/Equity

1.27

Debt/Cashflow

0.09

Investor Care

Shares Dilution (1Y)

1.09%

Diluted EPS (TTM)

-0.77

Peers (Alternatives to Novocure)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
10.2T
429.9M
-11.88% 44.84%
185.5K
28.0K
144.70% 331.94%
86.7B
17.9B
14.69% -0.88%
41.71
4.92
7.67% 29.32%
86.3B
6.1B
15.30% -16.82%
62.6
14.1
11.47% -18.42%
67.1B
18.9B
10.69% 8.01%
38.21
3.25
-6.81% -14.96%
61.8B
12.3B
11.14% 17.68%
69.9
5.01
10.11% 51.89%
43.9B
5.4B
8.87% -30.30%
30.09
8.18
5.29% -1.25%
MID-CAP
6.7B
998.4M
15.24% 17.79%
44.21
6.87
6.04% -19.01%
6.4B
806.4M
33.98% -14.84%
-331.15
7.96
20.10% -221.96%
3.9B
380.1M
-8.48% 5.83%
-29.57
10.69
18.85% -63.58%
3.6B
790.7M
-16.73% -66.49%
-273.58
4.7
19.65% -412.22%
SMALL-CAP
1.6B
126.8M
26.44% 24.39%
-26.38
14.01
34.44% -10.05%
1.1B
291.9M
9.49% -7.06%
-6.57
3.67
52.45% -57.74%
1.0B
795.9M
17.05% -10.97%
-131.34
1.33
8.11% 182.50%
606.7M
236.2M
-6.64% -29.40%
-16.43
2.57
-8.79% -175.19%

Financials for Novocure

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-0.5%543545538535546
Gross Profit-0.5%427429422420432
Operating Expenses2.9%497483467464441
  S&GA Expenses5.7%163154144137129
  R&D Expenses1.9%208204198201188
Earnings Before Taxes-20.8%-74.86-61.98-51.86-52.07-17.68
Net Income-19.7%-81.69-68.24-58.87-58.35-26.98
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets1.0%1,1741,1631,1501,1391,120
  Current Assets0.7%1,1021,0951,0811,0741,069
    Cash Equivalents-33.5%244367191209690
  Inventory-9.3%2730292423
  Net PPE12.0%3027252312
Liabilities1.1%729721714729707
  Current Liabilities4.2%141135128143125
  Long Term Debt-562----
    LT Debt, Non Current0.1%565564563562561
Shareholder's Equity0.8%445442436410413
  Retained Earnings-3.7%-741.16-714.58-690.57-685.93-659.47
  Additional Paid-In Capital2.6%1,1891,1581,1281,1001,074
Accumulated Depreciation-22----
Shares Outstanding0.2%105105105104104
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-3.9%49516183122
  Share Based Compensation0.6%100991019593
Cashflow From Investing-780.4%-510.99-58.04-216.41-144.83-259.38
Cashflow From Financing8.0%16152126593

Risks

What is the probability of a big loss on NVCR?

99.6%


Probability that Novocure stock will be more than 20% underwater in next one year

73.5%


Probability that Novocure stock will be more than 30% underwater in next one year.

42.7%


Probability that Novocure stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NVCR drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Novocure was unfortunately bought at previous high price.

Returns

Cumulative Returns on NVCR

18.2%


7-Year Cumulative Returns

32.5%


5-Year Cumulative Returns

-3.5%


3-Year Cumulative Returns

What are the long-term rolling returns for NVCR?

FIve years rolling returns for Novocure.

Which funds bought or sold NVCR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
6,974,000
6,974,000
0.08%
2022-11-22
CVA Family Office, LLC
-
-
-2,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
915,000
12,155,000
0.02%
2022-11-21
FourThought Financial, LLC
NEW
-
1,000
1,000
-%
2022-11-17
M&T Bank Corp
-
-
15,000
362,000
-%
2022-11-17
CENTRAL TRUST Co
UNCHANGED
-
1,000
2,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-86,000
-
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
77,000
901,000
-%
2022-11-15
Kingsview Wealth Management, LLC
REDUCED
-0.79
63,000
810,000
0.04%
2022-11-15
Baird Financial Group, Inc.
ADDED
0.54
109,000
1,203,000
-%

1–10 of 42

Latest Funds Activity

Are funds buying NVCR calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own NVCR

Novocure News

The Motley Fool

12 Top Stocks to Buy in December.15 hours ago

The Motley Fool

The Motley Fool

NVCR Fair Value

Recent SEC filings of Novocure

View All Filings
Date Filed Form Type Document
Nov 04, 2022
8-K
Current Report
Nov 03, 2022
4
Insider Trading
Oct 27, 2022
10-Q
Quarterly Report
Oct 27, 2022
8-K
Current Report
Oct 17, 2022
4
Insider Trading
Oct 07, 2022
4
Insider Trading
Sep 26, 2022
4
Insider Trading
Sep 19, 2022
4
Insider Trading
Sep 13, 2022
4/A
Insider Trading
Sep 12, 2022
4
Insider Trading

Latest Insider Trading transactions for NVCR

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-01
Leonard Frank X
ACQUIRED
-
-
6,830
President, CNS Cancers US
2022-10-13
Leonard Frank X
SOLD
-513,372
76.01
-6,754
President, CNS Cancers US
2022-09-22
Leonard Frank X
SOLD
-520,058
77
-6,754
President, CNS Cancers US
2022-09-15
Leonard Frank X
SOLD
-1,086,220
88.5194
-12,271
Chief Development Officer
2022-09-15
Leonard Frank X
ACQUIRED
39,446.6
7.15
5,517
Chief Development Officer
2022-09-09
Leonard Frank X
SOLD
-163,944
88
-1,863
Chief Development Officer
2022-09-08
Leonard Frank X
SOLD
-550,316
81.48
-6,754
Chief Development Officer
2022-09-06
Leonard Frank X
SOLD
-108,741
78.57
-1,384
Chief Development Officer
2022-09-02
GROENHUYSEN WILHELMUS CM
SOLD
-23,395
79.037
-296
Chief Operating Officer
2022-09-02
Shah Pritesh
SOLD
-21,261
79.037
-269
Chief Commercial Officer

1–10 of 50

Asaf Danziger
1170
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields (TTFields) devices for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and malignant pleural mesothelioma. The company markets its products in the European Union, the United Kingdom, Japan, and internationally. It has a clinical study collaboration agreement with MSD to study TTFields together with KEYNOTE, an anti-PD-1 therapy; and a strategic collaboration with Zai Lab (Shanghai) Co., Ltd. to commercialize its products in Greater China and establishes a development partnership intended to accelerate the development of TTFields in multiple solid tumor cancer indications. NovoCure Limited was incorporated in 2000 and is based in Saint Helier, Jersey.

NVCR Income Statement

2022-09-30
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended12 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Income Statement [Abstract]     
Net revenues$ 130,998$ 133,606$ 409,411$ 401,818$ 535,031
Cost of revenues29,74930,20685,97985,190114,877
Gross profit101,249103,400323,432316,628420,154
Operating costs and expenses:     
Research, development and clinical studies51,95648,141151,265144,372201,303
Sales and marketing41,39532,580124,02998,075137,057
General and administrative32,50931,23194,68395,116126,127
Total operating costs and expenses125,860111,952369,977337,563464,487
Operating income (loss)(24,611)(8,552)(46,545)(20,935)(44,333)
Financial expenses (income), net(1,194)1,9812,7435,5677,742
Income (loss) before income tax(23,417)(10,533)(49,288)(26,502)(52,075)
Income tax3,1592,5915,9435,3916,276
Net income (loss)$ (26,576)$ (13,124)$ (55,231)$ (31,893)$ (58,351)
Basic net income (loss) per ordinary share (in usd per share)$ (0.25)$ (0.13)$ (0.53)$ (0.31)$ (0.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)104,884,583103,731,147104,552,803103,281,380103,433,274
Diluted net income (loss) per ordinary share (in usd per share)$ (0.25)$ (0.13)$ (0.53)$ (0.31)$ (0.56)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)104,884,583103,731,147104,552,803103,281,380103,433,274

NVCR Balance Sheet

2022-09-30
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
CURRENT ASSETS:  
Cash and cash equivalents$ 243,805$ 208,802
Short-term investments726,515728,898
Restricted cash231807
Trade receivables, net87,55293,567
Receivables and prepaid expenses17,47817,025
Inventories26,79224,427
Total current assets1,102,3731,073,526
LONG-TERM ASSETS:  
Property and equipment, net29,74522,693
Field equipment, net11,98512,923
Right-of-use assets19,40518,267
Other long-term assets10,70712,086
Total long-term assets71,84265,969
TOTAL ASSETS1,174,2151,139,495
CURRENT LIABILITIES:  
Trade payables77,02672,600
Other payables, lease liabilities and accrued expenses64,05070,002
Total current liabilities141,076142,602
LONG-TERM LIABILITIES:  
Long-term debt, net564,677562,216
Deferred revenue3,9246,477
Long-term leases14,82712,997
Employee benefit liabilities4,0884,543
Other long-term liabilities222166
Total long-term liabilities587,738586,399
TOTAL LIABILITIES728,814729,001
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:  
Ordinary shares no par value, unlimited shares authorized; issued and outstanding: 104,942,941 shares and 103,971,263 shares at September 30, 2022 (unaudited) and December 31, 2021, respectively00
Additional paid-in capital1,188,8641,099,589
Accumulated other comprehensive income (loss)(2,306)(3,169)
Retained earnings (accumulated deficit)(741,157)(685,926)
TOTAL SHAREHOLDERS' EQUITY445,401410,494
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$ 1,174,215$ 1,139,495